To better treat adolescent and young adult (AYA) patients with various subtypes of Hodgkin and non-Hodgkin lymphomas (NHL), Andrew Evens, DO, speaks to the importance of primary care, screening access, and research.

While both are anti-CD20 antibodies, obinutuzumab is a glycoengineered type II CD20 antibody, and rituximab is a type I CD20 antibody, meaning a different mode of binding to CD20 antigen. | Image credit: Eleni - stock.adobe.com

Long-Term Data Show Favorable Survival Outcomes With G-Clb in Treatment-Naive CLL

By AJMC Contributor

May 1st 2025

Participants in the CLL11 trial and a smaller group of patients followed after study completion showed improved overall survival with obinutuzumab and chlorambucil (G-Clb) compared with chemotherapy plus rituximab or chemotherapy alone for chronic lymphocytic leukemia (CLL).

Liver cancer - Sebastian Kaulitzki - stock.adobe.com.jpg

Elevated HLA-G Seen in HCC Driven by Viral Infections, Fatty Liver

By AJMC Contributor

May 1st 2025

Increased levels of human leukocyte antigen G (HLA-G) were associated with inferior overall survival.

The results offer some of the first glimpses into real-world findings of the JAK inhibitor momelotinib, which was approved in 2023. | Image credit: mdaros - stock.adobe.com

Real-World Findings Confirm Clinical Data on Momelotinib in MF With Anemia

By AJMC Contributor

May 1st 2025

The results offer some of the first glimpses into real-world findings of the Janus kinase inhibitor in patients with myelofibrosis (MF) and anemia.

Fillingoutaformforaclinicaltrial | Image Credit: © KayExam/peopleimages.com-stock.adobe.com

Keep Patients at the Center of Clinical Research

By Maggie L. Shaw

April 30th 2025

Experts emphasize the need for enhanced clinical trial infrastructure in community oncology to ensure equitable access to innovative therapies for all patients.

...

107 108 109 110 111

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions